期刊文献+

抗菌肽作为潜在的生物被膜抑制剂的研究进展

Research progress of antimicrobial peptides as potential biofilm inhibitors
原文传递
导出
摘要 细菌对抗菌药物的耐药性已成为人类健康的重大威胁,生物被膜的形成显著增加了细菌对抗菌药的耐药性和宿主的先天防御,成为微生物的主要毒力因子。抗菌肽(antimicrobial peptides,AMPs)具有广谱抗菌特性和抗生物被膜活性,已成为潜在的治疗药物。本文综述了生物被膜的形成、耐药性及其相关感染,特别关注了AMPs的抗生物被膜潜力,强调了其优点、对浮游菌的作用机制、抗生物被膜机制以及与抗菌药物协同作用的抗生物被膜活性等,以期为AMPs在临床生物被膜相关耐药菌感染中的应用提供参考。 Bacterial resistance to conventional therapies has become a major threat to human health,and the formation of biofilms has significantly increased the resistance of bacteria to antibiotics and the innate defense of the host to become the main virulence factor of microorganisms.Antimicrobial peptides(AMPs)have broad⁃spectrum antimicrobial properties and anti⁃biofilm activity,which have become potential therapeutic drugs.This review described biofilm formation,drug resistance and associated infections,with particular attention to the anti⁃biofilm potential of AMPs,highlighting their advantages,mechanism of action against planktonic bacteria,mechanism of anti⁃biofilm,and anti⁃biofilm activity in synergistic with antibiotics,so as to provide references for the application of AMPs in clinical biofilm⁃related drug⁃resistant bacterial infections.
作者 陆章平 常彦斌(综述) 李可可 魏莲花(审校) LU Zhangping;CHANG Yanbin;LI Keke;WEI Lianhua(Ningxia Medical University,Yinchuan 750004,Ningxia;不详)
出处 《中国生物制品学杂志》 CAS CSCD 2024年第4期505-512,共8页 Chinese Journal of Biologicals
基金 国家自然科学基金(81960385) 甘肃省医学检验临床医学研究中心(21JR7RA676) 甘肃省人民医院院内基金(22GSSYD-58) 中医药管理局科研项目(GZK-2012-17)。
关键词 抗菌肽 生物被膜 耐药性 抗生物被膜机制 协同作用 Antimicrobial peptides(AMPs) Biofilm Drug resistance Anti⁃biofilm mechanism Synergy
  • 相关文献

参考文献3

二级参考文献85

  • 1Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappinscott HM. Microbial biofilms. Annu Rev Microbiol 1995; 49:711-745.
  • 2Werner E, Roe F, Bugnicourt A, et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2004; 70: 6188-6196.
  • 3Moskowitz SM, WEmerson JC, McNamara S, et al. Rando- mized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmono12011; 46:18~ 192.
  • 4Herrmann C~ Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy conceming killing ofbiofilm Pseudomonas aeruginosa. J lnfect Dis 2010; 202: 1585-1592.
  • 5Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N Spread of colistin-resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008; 7:391-397.
  • 6Bjamsholt T, Moser C, Jensen PO, Hoiby NE. Biofilm Infections. New York: Springer, 2010.
  • 7Costerton W, Veeh R, Shirtliff M, et al. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112: 1466-1477.
  • 8Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmono12009; 44: 547-558.
  • 9Hoiby N, Bjamsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-332.
  • 10Palmer RJ, Darveau R, Lamont R J, Nyvad B, Teles RP. Human oral bacterial biofilms: composition, dynamics, and pathogenesis. In: Bjamsholt T, Moser C, Jensen PO, Hoiby N, eds. Biofilm infections. New York: Springer, 2010: 35-68.

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部